Clinical Trials Directory

Trials / Conditions / Recurrent Platinum-resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer

7 registered clinical trials studyying Recurrent Platinum-resistant Ovarian Cancer.

StatusTrialSponsorPhase
UnknownA Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Week
NCT05145218
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
UnknownCamrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
NCT04068974
Peking Union Medical College HospitalPhase 2
UnknownStudy on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant O
NCT03467178
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 2
CompletedA Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (
NCT03398655
Vascular Biogenics Ltd. operating as VBL TherapeuticsPhase 3
CompletedEfficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resist
NCT02889900
AstraZenecaPhase 2
CompletedPhase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
NCT02028117
Akamis BioPhase 1
CompletedDose-finding Study in Platinum-Resistant Ovarian Cancer
NCT01653912
AccenturePhase 1 / Phase 2